Medically reviewed by Isabel Casimiro, MD, PhD Hypoparathyroidism is a rare condition characterized by the diminished ...

3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism. Hypoparathyroidism is a rare, complex ...

Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

It was a rough night for Patrick Mahomes at the 2025 Super Bowl. He threw a bunch of interceptions, got sacked a lot, and he ...

SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

"Until now, the only treatment option for adults with chronic hypoparathyroidism has been conventional therapy with calcium and active vitamin D supplementation to keep blood calcium levels normal ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic ...